Allan Rowley, Chief Executive of Medicsight, commented, "Previous research has shown Medicsight's ColonCAD significantly improves the performance of radiologists in the detection of polyps in CT colonography image data. The reduction in the numbers of false positives returned by our latest version of CAD is expected to further improve the performance of radiologists, by reducing the number of CAD marks which must be assessed when reviewing a patient dataset."
ColonCAD API 4.0 has been CE Marked and will be available for sale in Europe through Medicsight's network of partners.
More than 17,000 medical and industry professionals from over 95 countries will be attending this year's ECR which is taking place in the Austria Center, Vienna from 6-10 March. Visitors will be able to see demonstrations of the Medicsight ColonCAD software integrated into their partners' 3D advanced visualization workstations at the company's exhibition booth no 506 in Expo E.
* Data on file, Medicsight PLC
About MGT Capital Investments, Inc.
MGT Capital Investments, Inc. is a technology holding company that focuses on investments in the global healthcare information technology market. The Company has two subsidiaries, Medicsight PLC and Medicexchange PLC.
Medicsight PLC (AIM: MDST) is a UK-headquartered, research driven, leading developer of computer-aided detection (CAD) and image analysis software for the medical imaging market. The CAD software automatically highlights suspicious areas on computerized tomography (CT) scans of the colon and lung, helping radiologists to identify, measure and analyze potential disease and early indicators of disease. Medicsight's CAD software has been validated using one of the world's largest and most population diverse databases of verified patient CT scan data. Medicsight's ColonCAD(TM) and LungCAD(TM) softwa
|SOURCE MGT Capital Investments, Inc.|
Copyright©2009 PR Newswire.
All rights reserved